High dose recombinant tumour necrosis factor (rTNFα) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer
- 30 June 1995
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 31 (6) , 1009-1016
- https://doi.org/10.1016/0959-8049(94)00512-5
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Recombinant Human Tumor Necrosis Factor Administered as a 24-Hour Intravenous Infusion. A Phase I and Pharmacologic StudyJNCI Journal of the National Cancer Institute, 1988
- A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients.Journal of Clinical Oncology, 1988
- Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism.Journal of Clinical Oncology, 1988
- Phase I clinical trial of recombinant human tumor necrosis factorCancer Chemotherapy and Pharmacology, 1987
- Phase I study of recombinant human tumor necrosis factorCancer Chemotherapy and Pharmacology, 1987
- Cachectin and tumour necrosis factor as two sides of the same biological coinNature, 1986
- Tumor Necrosis Factor (TNF)Science, 1985
- Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor.Proceedings of the National Academy of Sciences, 1985
- Molecular cloning of mouse tumour necrosis factor cDNA and its eukaryotic expressionNucleic Acids Research, 1985
- An endotoxin-induced serum factor that causes necrosis of tumors.Proceedings of the National Academy of Sciences, 1975